StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.94−0.04 (-2.02%)

Close on Nov 17, 2026Market cap $155.54MP/E –Yield –

BridgeBio Oncology Therapeutics cash

Cash and short-term investments held at the end of each period.

BridgeBio Oncology Therapeutics's cash was $344.10M at Jun 30, 2026. For fiscal 2025 it was $425.50M, up 173.2% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$425.50M+173.2%
FY2024Dec 31, 2024$155.76M+62205.2%
FY2023Dec 31, 2023$250.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$344.10M+987.2%
Q1 FY2026Mar 31, 2026$388.90M+1376.0%
Q4 FY2025Dec 31, 2025$425.50M+173.2%
Q3 FY2025Sep 30, 2025$468.30M+2194.5%
Q2 FY2025Jun 30, 2025$31.65M+1644.3%
Q1 FY2025Mar 31, 2025$26.35M+1329.2%
Q4 FY2024Dec 31, 2024$155.76M+62205.2%
Q3 FY2024Sep 30, 2024$20.41M–
Q2 FY2024Jun 30, 2024$1.81M–
Q1 FY2024Mar 31, 2024$1.84M–
Q4 FY2023Dec 31, 2023$250.00K–

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?